Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000309088
Ethics application status
Approved
Date submitted
1/04/2010
Date registered
19/04/2010
Date last updated
23/03/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Carboplatin and Paclitaxel (Taxol) versus Carboplatin and Paclitaxel (Taxol) followed by Carboplatin for frontline chemotherapy in advanced ovarian carcinoma. A Hellenic Cooperative Oncology Group Study
Query!
Scientific title
Carboplatin and Paclitaxel (Taxol) (8 cycles) versus Carboplatin and Paclitaxel (Taxol) (4 cycles) followed by Carboplatin (4 cycles) for frontline chemotherapy in advanced ovarian carcinoma. A randomised phase III study of overall survival by the Hellenic Cooperative Oncology Group
Query!
Secondary ID [1]
1574
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Ovarian Cancer
256995
0
Query!
Condition category
Condition code
Cancer
257149
257149
0
0
Query!
Ovarian and primary peritoneal
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
PACLITAXEL (TAXOL): 175mg/m2 intravenous (i.v.) over 3 hours (h) only on day 1 of each cycle, cycles 1 to 4
CARBOPLATIN: Area under the curve (AUC)6 i.v. over 1h only on day 1 of each cycle, cycles 1 to 4
Followed by
CARBOPLATIN: 6 AUC i.v. over 1h only on day 1 of each cycle, cycles 5 to 8
Duration of therapy: 1 day per cycle. Cycles are repeated every 21 days.
Query!
Intervention code [1]
256172
0
Treatment: Drugs
Query!
Comparator / control treatment
PACLITAXEL (TAXOL): 175mg/m2 i.v. over 3h only on Day 1 of each cycle, cycles 1 to 8
CARBOPLATIN: AUC 6 i.v. over 1h only on Day 1 of each cycle, cycles 1 to 8
Duration of therapy: 1 day per cycle. Cycles are repeated every 21 days.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
258106
0
Overall Survival (OS)
Query!
Assessment method [1]
258106
0
Query!
Timepoint [1]
258106
0
3 years following randomisation. This outcome is assessed using clinical data records
Query!
Secondary outcome [1]
263713
0
Disease-Free Survival (DFS)
Query!
Assessment method [1]
263713
0
Query!
Timepoint [1]
263713
0
18 months from study initiation. This outcome is assessed by physical examination, laboratory evaluation of hematology and biochemistry, computed tomography (CT), bone scan (if indicated) etc.
Query!
Secondary outcome [2]
263714
0
To compare toxicity (especially neuroroxicity) between the two treatment arms
Query!
Assessment method [2]
263714
0
Query!
Timepoint [2]
263714
0
Toxicity is assessed after each cycle by laboratory evaluation of hematology and biochemistry, physical examination etc. A baseline neurological evaluation and then at every cycle is recommended.
Query!
Secondary outcome [3]
263749
0
Best Response Rate
Query!
Assessment method [3]
263749
0
Query!
Timepoint [3]
263749
0
Assessment of tumor response should be made every 4 cycles and at the end of the study (4 weeks following the completion of chemotherapy). Response is assessed by imaging methods (computed tomography [CT] scan).
Query!
Eligibility
Key inclusion criteria
Histologically confirmed epithelial carcinoma of ovarian origin, Federation of International Gynaecological Oncologists (FIGO) stage IIc, III or IV at laparotomy, regardless of measurable or non-measurable disease.
Patients with non measurable or evaluable disease with either elevated or normal cancer antigen 125 (CA-125) levels according to the baseline assessment are eligible for the study but they are not evaluable for clinical response to chemotherapy.
No previous chemotherapy or immunotherapy for this disease.
There is no maximum age restriction, provided that patients are biologically fit.
Laboratory values within the 2 weeks preceeding the start of the study treatment:
*White Blood Cell count (WBC) >3.5x10 ^9/l
*neutrophil count >1.5x10^9/liter (l)
*platelet count >100x10^9/l
*serum billirubin >1.5 miligrams (mg)/deciliter (dL)
*creatinine cleareance >50 milliliters (ml)/minute (min)
Performance status World Health Organization(WHO) <=2.
No symptoms or signs of cardiac insufficiency or acute coronary disease.
Informed consent in accordance with the dispositions of the Helsinki, Tokyo and Venice declarations . The informed consent is to be registered in the patients’ records.
Patients must be geographically accessible for treatment and follow-up.
Patients must be enrolled within six weeks after the definitive laparotomy.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Prior chemotherapy or radiation treatment
Other malignant tumor or tumor history, except for non melanoma skin cancer or radicaly excised in situ carcinoma of the uterine cervix
Performance status (WHO)>2
Absolute Neutrophil Count < 1.5x10^9/l or platelet count < 100x10^9/l.
History of atrial or ventricular arrhythmias and/or history of congestive heart failure, even if medically controlled. History of clinically and electrocardiographically documented myocardial infarction within the last 6 months.
Active infection or other serious underlying medical conditions which would impair the ability of the patient to receive protocol treatment, including prior allergic reactions to drugs containing chemophor, such as teniposide or cyclosporin.
Administration of other therapeutic drugs or hormonal therapy during the study period.
Patients with complete bowel obstruction and/or with brain metastases.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
4/04/2005
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
412
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
2552
0
Greece
Query!
State/province [1]
2552
0
Query!
Funding & Sponsors
Funding source category [1]
256728
0
Other Collaborative groups
Query!
Name [1]
256728
0
Hellenic Cooperative Oncology Group
Query!
Address [1]
256728
0
18, Hatzikostandi str, 11524, Athens
Query!
Country [1]
256728
0
Greece
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Hellenic Cooperative Oncology Group
Query!
Address
18, Hatzikostandi str, 11524, Athens
Query!
Country
Greece
Query!
Secondary sponsor category [1]
256012
0
None
Query!
Name [1]
256012
0
Query!
Address [1]
256012
0
Query!
Country [1]
256012
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
This is a randomized trial comparing carboplatin and paclitaxel (8 cycles) versus carboplatin and paclitaxel (4 cycles) followed by carboplatin (4 cycles) for frontline chemotherapy in advanced ovarian carcinoma. The main objective is to evaluate overall survival and. secondary endpoints are to evaluate disease-free survival, best response rate and to compare toxicity (especially neuroroxicity), between the two treatment arms.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
30960
0
Query!
Address
30960
0
Query!
Country
30960
0
Query!
Phone
30960
0
Query!
Fax
30960
0
Query!
Email
30960
0
Query!
Contact person for public queries
Name
14207
0
Eleni Papakostaki
Query!
Address
14207
0
18, Hatzikostandi str, 11524, Athens
Query!
Country
14207
0
Greece
Query!
Phone
14207
0
00302106912520
Query!
Fax
14207
0
Query!
Email
14207
0
[email protected]
Query!
Contact person for scientific queries
Name
5135
0
Aristotelis Bamias
Query!
Address
5135
0
Alexandra Hospital, Department of Clinical Therapeutics, 80 Vas. SofiasAthens 11528
Query!
Country
5135
0
Greece
Query!
Phone
5135
0
+30 210 3381546
Query!
Fax
5135
0
Query!
Email
5135
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF